Team

Mr. Alaia is a dedicated finance partner who thrives in high growth and fast paced environments. He began his career with the audit team at Sax LLP, after which he joined global pharmaceutical leader, Sanofi, where he specialized in accounting and finance. Prior to joining Immuneering, he was an integral part of the finance team at Immunomedics, assisting in building out the finance process and helping the business through successful commercialization of their lead product, Trodelvy. He is a CPA and holds a BS in Accounting from the State University of New York at Albany.

Naseem Alkaabi is a Senior Research Associate with strong experience in biotechnology and cancer research, specializing in mammalian cell culture, immunoassays, flow cytometry, and molecular biology techniques. She has worked in both academic and industry research settings, contributing to cancer immunotherapy research, antibody development, cell-based assays, and biomarker studies. Her work has supported drug discovery, translational research, and preclinical development through rigorous experimental design, data analysis, and cross-functional collaboration. Naseem earned a Bachelor’s degree in Medicine and Health Sciences from the University of Aden, a Biotechnology Certificate of Achievement, and formal training in Clinical Trials Design and Management.

Ms. Arcila is an accounting professional with over 20 years of accounting, accounts payable, and accounts receivable experience. She is responsible for accounting operations and Accounts Payable at Immuneering.

Hema Athawale is a recent graduate from California State University, San Marcos (CSUSM) with a Master’s Degree in Biotechnology. She gained lab experience working as a student researcher on an epigenetics project, and as a teacher’s assistant in both molecular biology and DNA/RNA technology lab classes at CSUSM. Ms. Athawale’s previous work experience includes working as an educator interacting with and delivering lessons to middle and high school students in India. She brings her expertise to Immuneering as a full-time Research Associate.

Ms. Axel is a highly skilled scientist with experience in academia (Nationwide Children's Hospital, Ohio, USA) and the pharmaceutical industry (Janssen/J&J in Belgium and USA). She has expertise in solid and hematologic tumors focusing on physiologically relevant models for tumor microenvironment and complex cell‐based assays to evaluate molecules with varying mechanisms of action. Moving from directing hypothesis driven biomarker research projects, internally and externally, Ms Axel transitioned to an operational role at Janssen executing biomarker strategies in clinical trials in early development. She graduated from Ohio State University with a BSc. in Molecular Genetics.

Pedram Banishahabadi has ten years of experience in the information technology (IT) field and is passionate about developing new technologies and staying abreast of the latest trends in the field. Prior to joining Immuneering, he held a number of IT systems positions including Systems Engineer at Interlaced.io, I.T. Responsive, dinCloud and iServe Residential Lending. He received an MBA from Nation University, an M.S. in engineering from Universiti Putra Malaysia and a continuing education certification in cloud engineering from UC San Diego.

Mr. Bookman has served as our Chief Legal Officer and Secretary since January 2023, and previously served as our General Counsel and Secretary from July 2021 to January 2023. Prior to joining us, Mr. Bookman served as the General Counsel and Secretary of Frequency Therapeutics, Inc., or Frequency, from January 2021 until July 2021, and the Deputy General Counsel and Secretary of Frequency from September 2019 until January 2021. Prior to Mr. Bookman’s role at Frequency, he was an associate at Latham & Watkins LLP, a leading international law firm where he worked on corporate transactional, securities and general business and governance matters, with an emphasis on representing high-growth technology and life sciences companies, from October 2012 until August 2019. Mr. Bookman serves on the board of directors of the Girl Scouts of Eastern Massachusetts, Inc., a non-profit organization. Mr. Bookman received his B.B.A., summa cum laude, in finance from the University of Miami and his J.D. from the University of Virginia School of Law.

Ms. Bruno brings over 25 years of experience in the life sciences industry, spanning biotechnology, medical device, and pharmaceutical drug development. She began her career at the bench in an analytical laboratory supporting the characterization of investigational products through pharmacokinetic profiling and pharmacodynamic endpoint assessment across clinical and non-clinical studies. Building on her scientific foundation, she transitioned into strategic Quality leadership, partnering with emerging and growth-stage biopharmaceutical companies to design, implement, and mature scalable, inspection-ready Quality frameworks aligned with global regulatory standards. Prior to joining Immuneering in February 2026, Ms. Bruno held Quality leadership roles at Entasis Therapeutics , Spyre Therapeutics , and Geron Corporation . Ms. Bruno holds a Graduate Certificate in Regulatory Affairs from Northeastern University, an M.S. in Biotechnology from Worcester State University, and a B.S. in Biology from Framingham State University. 

David joined Immuneering as Vice President, Corporate Communications in July 2026. He is a senior corporate communications leader with expertise in corporate media relations, patient advocacy, executive, financial and crisis communications, as well as issues management. Prior to joining Immuneering, David held communication leadership roles at Pfizer, Seagen, Biogen, City of Hope, Amgen, Merck and Disney. He earned a BA in journalism from the University of Maine and holds a management certificate from the University of Washington.   

Dominic Capasso has served as Associate General Counsel at Immuneering since May 2023. Prior to joining Immuneering, Mr. Capasso served in roles of increasing responsibility at Evelo Biosciences, Inc., most recently as Vice President, Corporate Counsel and Secretary. Prior to Evelo, Mr. Capasso was an associate at Cooley LLP and, before that, at Cravath, Swaine and Moore LLP, leading international law firms where he worked on corporate transactional, securities and governance matters. Mr. Capasso received his B.A., summa cum laude, from the University of Massachusetts at Amherst, and his J.D., magna cum laude, from the University of Pennsylvania Law School.

Jennifer joined Immuneering as Associate Director, Clinical Scientist in 2026. She has over a decade of experience in oncology clinical trials, with prior experience as a Clinical Scientist on Phase I-III trials at Novartis, Celgene, and Regeneron. Jennifer also has site experience as a Research Pharmacist at Jacobi Medical Center and as a Study Coordinator at Dana-Farber Cancer Institute, as well as vendor experience in clinical trial technology products (mobile eCOA and EDC). Jennifer earned her PharmD from the University of Maryland School of Pharmacy and her B.A. in Child Development and Community Health from Tufts University. 

Dr. Conrad has over 13 years of experience in analytical, formulation, and manufacturing process development. Prior to joining Immuneering in April 2025, Dr. Conrad held roles of increasing responsibility at Hikma Pharmaceuticals developing generic injectable medicines culminating in his leadership of an integrated group responsible for end-to-end product development. He also worked previously for Boehringer Ingelheim in R&D and Operations. Dr. Conrad received his B.S. in Chemistry and his Ph.D. in Physical Chemistry from Kent State University.

Caitlin serves as Associate Scientist on the Discovery team at Immuneering, contributing to high‑throughput screening efforts and the advancement of lead compound translation. She holds a Master’s degree in Chemistry from Queen’s University, and a Bachelor of Science degrees in Biochemistry and Molecular Biology from the University of Toronto.

Dr. DeCorte has served as our VP of Chemistry since April 2025. Prior to joining Immuneering, he served as VP of Business Development for Symeres, a transatlantic chemistry and drug discovery CRO with laboratories in Europe and the US. He is also the founder of Kodib, LLC, a consultancy firm that provides drug discovery and early development expertise to pharmaceutical and biotech organizations.

In 1993, Dr. DeCorte joined Johnson & Johnson. Over the course of his 20+ year career at J&J, he worked in the areas of HIV, mycology, oncology, pain, inflammation and metabolic disease and served as the scientific founder and head of chemistry of Entura, a natural products-based drug discovery venture of J&J.

Dr. DeCorte is a co-inventor of IMM-1-104, a compound that is currently being evaluated clinically by Immuneering for the treatment of advanced solid tumors including pancreatic cancer. He is also the co-inventor of INTELENCE, Johnson & Johnson’s first FDA-approved non-nucleoside reverse transcriptase inhibitor for the treatment of HIV.

Dr. DeCorte completed his undergraduate education in Bioengineering at the University of Gent, Belgium, followed by graduate and postdoctoral work in organic chemistry at the Université de Rennes, France, the University at Albany, NY, and Vanderbilt University in Nashville, TN.

Dr. DeCorte is the co-author of 29 peer-reviewed research papers and is listed as an inventor on more than 30 patents and patent applications.

Mr. Drew brings over 15 years of experience working in cloud computing operations to Immuneering, with expertise in high performance computing and big data for multi-region and international operations. After graduating from the University of Florida with a B.S. in Decision Information Sciences, he worked for several technology startups, refining his expertise in both software engineering and cloud operations with a strong focus on security. He lost his younger brother at age 15 to leukemia and is passionate about utilizing his skills, time and technology to contribute to the goal of helping treat and potentially cure cancer.

Ms. Flannery joined Immuneering’s clinical team in October 2022. Prior to joining Immuneering, she held a variety of clinical positions in the pediatrics and dermatology fields before joining a clinical research organization as Lead Medical Communications Specialist with a focus on reporting, product training and patient education. Ms. Flannery earned a bachelor's degree in international studies and public health from Indiana University.

Ms. Foley has over 18 years of experience in clinical trials, spanning both CRO and Biotech companies. She started as a Clinical Research Associate, grew into project management and has most recently been leading research programs and clinical operations departments. From her commitment to making a difference in the lives of patients, she has developed a depth of knowledge in, as well as a true passion for, early Phase 1 oncology trials. She brings a creative approach to management, including strong teamwork, risk mitigation, problem solving, PI engagement and quality data results. She graduated from Tulane University with a Bachelor of Science in Cell and Molecular Biology.

Dr. Fowler brings deep expertise in biology and computational biology to our team. He joined Immuneering after completing his Ph.D. in Chemical Engineering at the Massachusetts Institute of Technology. His doctoral research was focused on computational immunology and signal integration in immune cell biology, and he conducted research at Harvard Medical School.

David joined Immuneering in 2026 as Senior Research Associate. Prior to joining Immuneering, David worked at Escient Pharmaceuticals, where he ran high-throughput screening and helped bring the company’s lead project to the clinic. David earned his B.S. in Biology from UCSD.  

Dr. Funt’s focus is in synthesizing actionable insight from complex, heterogeneous high-dimensional data. He earned his Ph.D. in Computational and Systems Biology from MIT’s Biology Department. His thesis research, at both the Massachusetts Institute of Technology and the Broad Institute, focused on mapping evolutionary pathways of drug resistance from genomic and transcriptomic profiling of the pathogen Candida albicans.

Mr. Gengos has served as our Chief Financial Officer and Treasurer since July 2026. Prior to joining Immuneering, Mr. Gengos served as Chief Financial Officer and Head of Corporate Development at Terns Pharmaceuticals from February 2025 to May 2026, which Merck & Co., Inc. acquired for $6.7 billion. Previously, he served as Chief Financial Officer and Chief Business Officer of Athira Pharma, Inc. (now LeonaBio, Inc.) from May 2023 to October 2024 and Chief Business Officer of Cyteir Therapeutics, Inc. from February 2020 to  February 2023, where he led the finance organization that successfully completed the company's initial public offering. Earlier in his career, he served as Chief Executive Officer of ImmunoCellular Therapeutics, Ltd. from December 2012 to December 2016, and Neuraltus Pharmaceuticals, Inc. from February 2010 to August 2012, providing strategic and financial leadership across oncology and neurodegenerative disease programs. In addition, Mr. Gengos was Vice President of Strategy and Corporate Development at Amgen Inc. from October 2002 to February 2010, where he helped shape the company's long-term strategic priorities and business development initiatives. He began his career at Morgan Stanley in 1986 and later joined McKinsey & Company from September 1991 to June 1998, advancing from Associate to Senior Engagement Manager.    

Mr. Gengos holds an MBA from the UCLA Anderson School of Management and a BS in Chemical Engineering from the Massachusetts Institute of Technology.

Ms. George started her career at PwC in the Pharma/Life Sciences Assurance practice, where she provided audit services to clients, including guidance on financial reporting requirements and internal controls compliance. Prior to joining Immuneering, Ms. George led FinTech Accounting and Operations at Advent Intermodal Solutions, where she collaborated with the commercial organization to build the digital payments and accounting infrastructure essential to support fast growth and international expansion. Ms. George received her B.S. in Accounting from Rutgers University, New Brunswick, NJ and is a Certified Public Accountant in New Jersey.

Dr. Gutierrez is a highly motivated, results-driven clinical research leader with medical background and about 20 years of experience in clinical drug development. Her research experience involves variety of investigational products (small molecule, cellular therapies, devices) and therapeutic areas, with focus on early phase Oncology. She combines deep industry knowledge with a proven track record of clinical trials execution across multiple functions. Dr. Gutierrez gained her MD degree in Smolensk State Medical Academy (Russia), and entered the biopharmaceutical industry after completing her clinical residency in internal medicine and fellowship in cardiology. She spent over 10 years working at the clinical CROs, including Pharm-Olam International and Sarah Cannon Development Innovations. Most recently, Dr Gutierrez has been leading Clinical and Safety Operations at Bellicum Pharmaceuticals, Houston-based biotech company focusing on cellular therapies.

Dr. Hall has served as our Chief Scientific Officer since November  2019. He also served as the Founder and Chairman of the board of directors of BioArkive, Inc., a privately held biotechnology services company from January  2019 until December  2021. Prior to that, Dr. Hall served as the Chief Executive Officer of Asellus Therapeutics, LLC, a privately held biotechnology company, from July  2015 until May  2018, and as the Head of Translational Medicine of Oncology at Medimmune, LLC, the biologics division of AstraZeneca Pharmaceuticals LP, from July  2014 until July  2015, before transitioning to executive discovery roles in biotechnology. From November  2008 until July 2014, Dr. Hall served in roles of increasing responsibility at Johnson & Johnson, a multinational corporation that develops medical devices, pharmaceuticals and consumer packaged goods, culminating in his role as the Head of Biomarkers of the Hematologic Disease Area Stronghold, where he led translational efforts for Sylvant^® and Imbruvica^® through clinical development. Dr. Hall has extensive drug development and leadership experience ranging from early drug discovery through translational clinical sciences, including multiple drug registrations. Dr. Hall has extensively published in the areas of tumor microenvironment (TME) and translational sciences, and holds multiple patents for drug pharmacology and discovery. He was also a tenure-track Assistant Professor at Ohio State University where his laboratory focused on the development of human TME-aligned models to better translate preclinical data into the clinic and discover novel biomarkers. Prior to Dr. Hall’s career in life sciences, he served in the United States Air Force and worked as an investment banker. Dr. Hall received his B.S. in biochemistry from Ohio State University, his Ph.D. in immunology and cancer biology from West Virginia University, and completed his post-doctoral fellowship in cancer cell epigenetics at St. Jude Children’s Research Hospital.

Jessie Haupt holds a B.A. in History from the University of California at Santa Cruz. After earning a Certificate of Paralegal Studies from UC Berkeley Extension, she worked for several years as a paralegal at personal injury law firms. Now as a member of the Operations Team, she heads laboratory procurement and facilitates smooth day-to-day lab operations.

Vinny Hayreh, MD, is a physician executive with extensive experience in oncology clinical development, medical affairs, and pharmacovigilance across global pharmaceutical and biotechnology organizations. She currently serves as Immuneering’s Vice President of Clinical Development, leading oncology programs from early clinical development through late-stage trials. She is also the Founder and CEO of Hayreh LLC, a pharmaceutical and biotechnology consulting firm providing clinical strategy, medical monitoring, and pharmacovigilant support for oncology programs. Previously, she held senior leadership roles including Senior Medical Director at Janssen Pharmaceuticals (Johnson & Johnson), Clinical Trial Lead (Medical Director) at Bristol Myers Squibb, Global Medical Affairs Leader and Global Safety Physician at AstraZeneca, and Senior Manager in Global Safety and Medical Communications at Amgen. Vinny received her medical degree from Grace University and completed post-graduate training at the University of California, Los Angeles.

Dominique Hinds has served as Administrative Assistant at Immuneering since May 2023. Prior to Immuneering, Ms. Hinds served in the United States Navy as an Operations Specialist on board the USS Essex LHD-2. While onboard, Ms. Hinds focused on creating the ship's operational schedule serving more than five-thousand sailors and marines. She is currently pursuing a B.A. in Business Administration at Western Governors University.

Dr. Hughes, Ph.D. is responsible for manufacturing process development and scale-up, and production of drug supplies for clinical trials according to cGMP requirements. Prior to joining Immuneering, Dr. Hughes held roles of increasing responsibility at Cidara Therapeutics, where he led the CMC development of REZZAYO™, a novel drug used for the treatment and prevention of systemic fungal infections, from Phase 1 through successful NDA and MAA approval and commercial launch. Prior to his work at Cidara, he held roles of increasing responsibility with Boehringer-Ingelheim’s Product and Process Development group for generic injectable drugs, culminating in its acquisition by Hikma Pharmaceuticals. Subsequent to the acquisition, he served as the Director of R&D for Hikma injectable products until December 2015. He also worked previously for PharmaForce, and Sonus Pharmaceuticals. Dr. Hughes received his Ph.D. in Organic Chemistry from the University of Notre Dame and completed a postdoctoral fellowship in Clinical Chemistry at the University of Washington School of Medicine. He received his B.S. in Chemistry from Eastern Washington University.

Jyoti joined Immuneering as Director, Quality Systems and Compliance in 2026. She brings more than 14 years of quality assurance and quality systems experience in the biotech industry, including building quality management systems from the ground up. Prior to joining Immuneering , she held quality roles at SpringWorks Therapeutics, Resilience, bluebird bio, Organon Teknika, and Merck. Jyoti holds an M.S. in Environmental Science from the University of North Carolina and a B.S. in Chemistry from Carnegie Mellon University. 

Mr. Kim is passionate about utilizing technology to accelerate research and development in the field of biomedicine. Prior to obtaining his M.S. in Biomedical Informatics from the Sackler Institute of Graduate Biomedical Sciences at NYU School of Medicine, he spent over five years working as a software implementation consultant specializing in the life sciences industry, where he led projects to configure, deploy, and manage the enterprise software development life cycle. He also graduated with a B.S./M.S. in Biomedical Engineering from Northwestern University.

Dr. King is a pharmaceutical professional with over 16 years of drug discovery and development experience (Janssen R&D/Johnson & Johnson; SmithKLine Beecham). With experience ranging from early drug discovery and preclinical/translational sciences. Dr King gained his B.Sc. from the University of Leicester, UK, in Biological Sciences in 1996, and his Ph.D. in Diabetes and Endocrinology in 2000, from the University of Liverpool, UK. After 2 years of postdoctoral training, Dr King joined Janssen Pharmaceuticals in 2002 at the Beerse site in Belgium, as a Scientist and Senior Scientist, in the Metabolic Disorders and Oncology Teams. He led the preclinical oncology in vivo team, where he contributed to numerous NME declarations and IND filings. As part of the Oncology Biomarkers Team, he was responsible for the Ex Vivo Center of Excellence for humanized model development. In 2012, Dr King joined the Molecular Imaging Team at the Janssen Spring House site in USA and lead the imaging program to support the Oncology Therapeutic Area.

Dr. Kolitz brings expertise in teasing apart biological mechanisms to our team. She conducted her postdoctoral research in Biological Engineering at the Massachusetts Institute of Technology, after earning a Ph.D. in Biophysics and Biophysical Chemistry from the Johns Hopkins University School of Medicine.

Kyra Liebson holds a Bachelor of Science degree in Cell and Molecular Biology from the University of South Florida. At USF she researched the effects of sodium saccharin on B-cell lymphoma proliferation in A20 cells. She also holds a Bachelor of Science degree in Marketing from SUNY Oswego, and has an extensive background in marketing and advertising. Ms. Liebson has a passion for science, music, and operations and brings her research skillset, diligent work ethic, and a commitment to excellence to her work at Immuneering.

Ms. Martin has several years of experience in office administration in various industries, as well as a broad background in customer relations, social media and marketing, human resources and recruiting, and finance. She holds a B.S. in Communications from Fitchburg State University.

Dr. Matushansky has served as our Chief Medical Officer since March 2025. Prior to joining Immuneering, Dr. Matushansky served as Chief Medical Officer at Sail Biomedicines, a Flagship Pioneering biotechnology company, from July 2023 to January 2025, where he built out and led the clinical/medical, translational, operational and regulatory functions. Prior to that, Dr. Matushansky was SVP and Global Head of Oncology Development at Ipsen S.A., a global specialty-care biopharmaceutical company, from July 2022 to June 2023, where, among other programs, he oversaw the completion of NAPOLI-3 leading to the approval of NALIRIFOX for first-line pancreatic cancer. Dr. Matushansky also served as Chief Medical Officer and Global Head of Research and Development at Hookipa Pharma Inc., a biopharmaceutical company, from April 2017 to July 2022, where he was responsible for bringing novel arenavirus technology from early preclinical research to clinical proof-of-concept. He also served as Global Head of Oncology Early Development at Daiichi Sankyo from November 2015 to April 2017, leading the company’s international research unit focused on early oncology therapeutic programs, and was Global Head at the Gene & Cell Therapy Unit and earlier the Global Clinical Program Head within the Oncology Translational Medicine Unit at Novartis from June 2012 to November 2015. Dr. Matushansky began his career in academia at the Columbia University Medical Center, where he founded and directed a sarcoma center and ran a laboratory focused on the molecular basis of sarcomas. Dr. Matushansky continues to dedicate time treating sarcoma patients as an attending physician. Dr. Matushansky earned his B.A. from Columbia University and his M.D. and a Ph.D. in molecular biology from Albert Einstein College of Medicine. Dr. Matushansky performed his internal medicine residency at New York Presbyterian Hospital/Weill Cornell Medical Center, and completed a fellowship in medical oncology and a post-doctoral research fellowship in cancer biology at the Memorial Sloan Kettering Cancer Center.

Mr. Mead began his career at PwC in the Pharma/Life Sciences Assurance practice. Throughout his tenure, he provided various audit services to clients, including guidance on internal controls compliance, financial reporting requirements, and various technical accounting topics. Mr. Mead received his B.S. in Accounting from Providence College, and is a Certified Public Accountant in New Jersey.

Ms. Morales has served as our Senior Vice President of Finance, Chief Accounting Officer and Treasurer since February 2026, and previously served as Chief Accounting Officer and Treasurer since July 2023, Vice President, Finance and Treasurer from August 2022 to June 2023 and Vice President, Finance from May 2021 to July 2022. Prior to joining us, Ms. Morales served as Strategic Finance Business Partner at Gilead Sciences, Inc. (“Gilead”), a biopharmaceutical company, from October 2020 to May 2021, where she oversaw the integration of the research and development organization of Immunomedics, Inc. (“Immunomedics”) following its acquisition by Gilead in October 2020. From April 2018 to October 2020, she served as Director and Assistant Controller at Immunomedics, an antibody drug conjugate company, where she oversaw the annual operating budget, forecasting and business planning. From May 2014 to April 2018, Ms. Morales held roles of increasing seniority at L’Oréal S.A., a personal care company, most recently as Director of Finance and Global Brand Controller of the L’Oreal Professional Products Division, where she oversaw and managed all financial and accounting functions. Ms. Morales is a CPA and began her career as an auditor for Pricewaterhouse Coopers. She earned her B.S. in Accounting and Business with honors from the State University of New York at Albany.

Dr. Nair has extensive leadership experience, and an impressive track record of developing effective strategies to mobilize cross-functional teams toward success in drug discovery, translational research and biobanking. Prior to joining Immuneering, he co-founded and served as the Chief Executive Officer of BioArkive, an innovative contract research group providing oncology research support and biosample management. Before BioArkive, Dr. Nair provided key scientific leadership and research support for multiple wholly-owned preclinical and drug discovery programs at Asellus Therapeutics. He also helped to build and expand ex vivo and in vitro research for multiple pharmaceutical clients at Molecular Response, where he coordinated the establishment and maintenance of diagnostic labs under CAP/CLIA environment, as well as IRB-approved tissue collections for translational studies. Dr. Nair earned his Ph.D. in Medical Microbiology and Immunology from the College of Veterinary Medicine at the University of Georgia, and finished his post-doctoral training at the Pritzker School of Medicine at University of Chicago.

Ms. Neufeld has served as our Chief People Officer since October 2022. Prior to joining us, Ms. Neufeld served as Chief Human Resources Officer of Luzsana Biotechnology (“Luzsana”) from August 2021 to October 2022, where she, as part of the executive team, helped establish Luzsana globally as a subsidiary of Hengrui Medicines. Previously, she was the Vice President, People, at Prevail Therapeutics from September 2019 to August 2021, until its acquisition by Eli Lilly. Prior to that, from August 2015 through September 2019, Ms. Neufeld was the Head of Human Resources at Intercept Pharmaceuticals, and from January 2014 to July 2015 was the Global Head of Human Resources for NPS Pharma until it was acquired by Shire Pharmaceuticals. From April 2009 to January 2014, she held positions of increasing responsibility at Daiichi Sankyo Pharma Development, most recently serving as Director of Human Resources. Earlier in her career, from November 2002 to April 2009, Ms. Neufeld held various human resources positions at Johnson & Johnson, including Manager of Human Resources in the consumer division and its oncology company called Ortho Biotech. Ms. Neufeld earned a B.A. in psychology from the American University and an M.S. in career counseling and organization development from Johns Hopkins University.

Brian Nguyen earned his B.S. in Biochemistry from the University of California, Los Angeles. He began working as a lab assistant at the University of California, San Diego and eventually became a lab manager. He transitioned to industry working in a high-throughput screening drug discovery program. In 2022, he joined Immuneering.

Scott Nguyen assumed the role of Head of Information Technology at Immuneering in August 2023. Preceding his tenure here, Mr. Nguyen held the position of IT Director at Spectrum Pharmaceuticals from May 2020 to August 2023. Prior to his engagement at Spectrum, he served as the leader of the IT Infrastructure department at Halozyme Therapeutics, where he spearheaded the implementation and maintenance of all Enterprise systems, alongside the development and upkeep of IT policies and procedures, from June 2007 to February 2020.

Dr. Nord is a cell biologist, with experience studying the cell cycle and how the eukaryotic cell can utilize proteins for distinctly different roles in interphase and mitosis, respectively. Dr. Nord earned his B.S. in Biochemistry and Cell Biology, as well as his Ph.D. in Cell Biology at the University of California, San Diego. Dr. Nord’s research focused on the interactions between nuclear transport receptors and the small GTPase RAN, which together regulate subunits of the nuclear pore complex in events ranging from mitotic spindle assembly to reformation of the nuclear pore as the cell exits mitosis and cytokinesis and re-enters interphase.

Ms. Perez Diaz is an experienced professional with over ten years of experience in the field of clinical research. With a diverse background in various areas of the industry, she has developed a comprehensive skill set, particularly in project management, study start-up, regulatory compliance, and clinical operations. Doris obtained her bachelor’s degree in biology from the University of Louisville, where she gained a solid foundation in the life sciences. She embarked on her career in dermatopathology, where she honed her analytical and research skills. However, driven by her passion for advancing medical knowledge, she transitioned to the field of clinical research.
Throughout her career, Ms. Perez Diaz has had the opportunity to work at different levels within the clinical research landscape. She has gained valuable insights and perspective working at the site level, collaborating with CROs, and most recently, making the transition to the biotech industry. This multifaceted experience has equipped her with a well-rounded understanding of the industry’s intricacies and the ability to approach challenges from various angles. Her experience spans across all phases of clinical trials, including post-market studies, and encompasses different therapeutic indications and medical devices.

Mr. Peterson has a technical background in IT and customer service which he has brought to his role as Logistics Manager. He also serves roles in facilities maintenance and building security.

Dr. Pillai is a Cancer biologist with more than 16 years of experience in basic and translational cancer research. He devoted over a decade into investigating the molecular features of Disseminated Tumor Cells (DTCs) from the bone marrow of breast cancer patients, and studying their role in disease progression and metastasis at the Department of Surgery, Washington University School of Medicine in St Louis. Dr. Pillai has also studied and published on the mechanisms of cell death regulation in tumor cells and its role in tumor progression. Dr. Pillai earned a Ph.D. from Indian Council for Agricultural Research (Central Institute of Fisheries Education), India and completed post doctoral research at Saint Louis University and Washington University in St Louis.

Dr. Piña brings years of experience in cell and molecular biology, biochemistry, and genetics to Immuneering. Prior to joining Immuneering, Dr. Piña did postdoctoral work at UCSD. He researched the crosstalk between cell cycle progression and the functional capacity of the endoplasmic reticulum, making significant contributions to the field and authoring several high impact publications. He completed his Ph.D. in Cell and Molecular Biology from Stanford University. The focus of his thesis was to investigate the molecular function of uncharacterized ER-localized proteins and their regulation by the protein phosphatase, Calcineurin. He received his B.S. from the University of Arizona, Tucson in Plant Sciences.

Jennifer Quach has served as Operations Assistant at Immuneering since April 2023. During undergrad, she gained experience in lab work, administrative work, and medical assistance. She strives to use her evolving knowledge and experience to make a positive impact in the community. As part of the Operations Team, Jennifer is dedicated to supporting lab operations within cross-disciplinary teams at Immuneering. She holds a B.S. in Biology from the University of California, San Diego.

Mr. Sebastian brings over 13 years of extensive technical accounting, financial reporting and internal controls expertise. Prior to joining Immuneering, Mr. Sebastian was a Director at PwC in the SEC Services Group of the National Quality Office where he advised clients on their SEC reporting. He started his career at PwC in the Pharma/Life Sciences Assurance practice where he provided audit services to his clients, which included advising them on technical accounting topics in addition to financial reporting requirements and internal controls. Stephen received his B.S. in Accounting from King’s College, Wilkes Barre, Pennsylvania and is a Certified Public Accountant in New Jersey.

Dr. Shiell has over 10 years of regulatory affairs experience, focusing on regulatory strategies for oncology drug development. Before joining Immuneering, Adam was the regulatory lead for clinical research at Flatiron Health, working on novel ways of using real-world evidence for regulatory purposes. Prior to Flatiron Health, Adam worked in a variety of regulatory affairs roles at Eli Lilly & Company, supporting oncology compounds in both early and late phase development. Adam received his PharmD from the University of Minnesota and BA in Biology from Carleton College, as well as completed the American Course on Drug Development and Regulatory Sciences through the University of California San Francisco.

Ms. Standard is a biotechnology quality management system and project management professional. After completing her Master’s of Science degree at Binghamton University in New York, she began her career supporting drug discovery efforts from small-molecule synthetization through IND-enabling studies at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California. Ms. Standard was integral in developing the biorepository Quality Management System at BioArkive, Inc., and in coordinating the company’s accreditation efforts for ISO 20387:2018 and the College of American Pathologist’s Biorepository Accreditation Program (CAP/BAP). While at BioArkive, she provided quality and project management support to critical Immuneering projects prior joining the Immuneering team, where she will support a growing pipeline of novel oncology drugs.

Loretta Sullivan, MD, MPH, has dedicated her life to improving global health. Over the last decade, she has held clinical leadership roles within the biopharmaceutical industry, including Genentech/Roche, Lilly, Astellas, J&J, ALX Oncology and Clovis Oncology. Prior to joining industry, Dr. Sullivan worked as an epidemiologist with the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and various non-governmental organizations in over 30 countries. Dr. Sullivan earned her undergraduate degree from Dartmouth College, her MPH in epidemiology at UCLA and her medical degree at the University of Colorado with an internal medicine residency at UCLA and hematology/oncology fellowship at Stanford. She is a veteran, having served in the U.S. Public Health Service, and she is fluent in five languages. Loretta lives in Denver, Colorado, with her husband and three sons. In her spare time, she plays USTA tennis and loves to ski.

Dr. Travesa has extensive experience in cancer research, ranging from genetics to tumor cell biology. During her years in academic research labs (Scripps Research and UCSD), she successfully contributed to the discovery of key molecular mechanisms involved in cell proliferation and malignant transformation. Dr. Travesa has also provided critical scientific advancements to preclinical and drug development programs. Dr. Travesa’s leadership fosters highly collaborative environments focused on delivering high quality data and enhancing the drug discovery process.

Kurt Walsh’s scientific background is primarily as a scientist and engineer in academia. Mr. Walsh earned a B.Sc in Biomolecular Engineering at UC Santa Cruz, where he performed research to understand the effects of small molecule drugs on the signaling dynamics of primary bovine chondrocytes. After UC Santa Cruz, Mr. Walsh went on to earn an M.S. in Biomedical Engineering at UC San Diego, where his research focus was in tissue engineering, cell-ECM signaling dynamics and cell-ECM biomechanics.

Dr. Wang has been working on integrating computational approaches and biological data to investigate the biology underlying human diseases for over 8 years. He earned his Ph.D. in Bioinformatics from Department of Information and Communication Engineering, Huazhong University of Science and Technology, China. During his Ph.D. career, he spent two years in Genetics at Dartmouth College as a visiting scholar. His major research focus was computationally identifying novel biomarkers for predicting survival outcomes in breast cancer. During his postdoctoral research in the Department of Biomedical Data Science at Geisel School of Medicine at Dartmouth he worked on drug repositioning, novel biomarkers identification, and patients ‘intrinsic’ subsets classification in Systemic Sclerosis (SSc, a rare autoimmune disease) in the Whitfield lab. Frank then became a research scientist in the same lab and continued his computational research in SSc. He has interest and expertise in performing computational analyses in different biological data types including microarray, DNA methylation, ChIP-seq, single-cell/bulk RNA-seq, and ATAC-seq data.

Patrick Xin has served as Senior Director of Clinical Data Management since December 2025, leading the company’s clinical data strategy and execution across global programs to support high-quality regulatory filings, scientific presentations, and publications. Prior to joining Immuneering, Patrick served as Executive Director at Arcturus Therapeutics, leading integrated biometric data management and statistical programming functions, and as Director of the Clinical Research DataCore at NYU Langone Health.
Patrick holds an M.S. in Computer Science from New Jersey Institute of Technology, an M.A. in Biochemistry from City University of New York, and a B.S. in Pharmaceutical Science from Fudan University, China

Ms. Yamamura has several years of experience with a broad range of disease models of inflammation, immunology, and oncology. She attended Colgate University where she studied Cellular Neuroscience and Psychology.

Dr. Zeskind has served as our Co-Founder, President, Chief Executive Officer and a member of our board of directors since February 2008. Dr. Zeskind received his S.B. in electrical engineering and computer science and his Ph.D. in bioengineering from Massachusetts Institute of Technology, or MIT, and his M.B.A. from Harvard Business School, where he was recognized as a Baker Scholar, the highest award for distinction.

Dr. Zhang extracts actionable insights from genomic data by combining cutting-edge data science techniques with expertise in experiment design and cancer biology. During her data science fellowship at The Data Incubator, she utilized distributed computing, network analysis, and machine learning to reveal patterns within large textual and numerical datasets. She graduated from the Massachusetts Institute of Technology with a B.S. in Physics, and Duke University with a Ph.D. in Genetics and Genomics. In her doctoral work, she developed novel experimental and bioinformatic methods to generate and analyze terabytes of next-generation sequencing data towards understanding the mutational underpinnings of lymphoma.